Protein Expression Affects Odds of Lymphoma Survival
LMO2 protein raises chances of survival in diffuse large B-cell lymphoma patients
FRIDAY, Dec. 28 (HealthDay News) -- In patients with diffuse large B-cell lymphoma, those who express the LMO2 protein respond better to treatment with anthracycline-based regimens with or without rituximab, according to a report published online Dec. 17 in the Journal of Clinical Oncology.
Yasodha Natkunam, M.D., Ph.D., of Stanford University Medical Center in Stanford, Calif., and colleagues conducted a study of 263 patients treated with anthracycline-based chemotherapy and 80 who received the therapy plus rituximab. The original biopsies were analyzed for the expression of LMO2.
Higher progression-free and overall survival rates were associated with LMO2 expression in patients in the anthracycline-based treatment group and in the anthracycline-rituximab group. In both cases LMO2 expression was a significant prognostic indicator independent of the clinical International Prognostic Index.
"Similar to its mRNA expression, LMO2 protein expression is significantly correlated in univariate and multivariate analyses with improved overall survival and progression-free survival in diffuse large B-cell lymphoma patients," the authors conclude. "After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed diffuse large B-cell lymphoma patients to optimize their clinical management."